Marshall Wace
BCYC

Marshall Wace’s Bicycle Therapeutics BCYC Stock Holding History

Marshall Wace’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
377,335
+338,540
+873% +$1.93M ﹤0.01% 1860
2025
Q4 		$275K Buy
+38,795
New +$286K ﹤0.01% 2486
2024
Q4 		– Sell
-330,258
Closed -$7.47M – 2584
2024
Q3 		$7.47M Buy
330,258
+241,271
+271% +$5.57M 0.01% 864
2024
Q2 		$1.8M Buy
+88,987
New +$2.01M ﹤0.01% 1427
2023
Q3 		– Sell
-9,271
Closed -$237K – 2197
2023
Q2 		$237K Sell
9,271
-67,378
-88% -$1.56M ﹤0.01% 2202
2023
Q1 		$1.63M Buy
76,649
+67,378
+727% +$1.69M ﹤0.01% 1566
2022
Q4 		$274K Hold
9,271
– – ﹤0.01% 2593
2022
Q3 		$216K Sell
9,271
-70,852
-88% -$1.69M ﹤0.01% 3062
2022
Q2 		$1.34M Buy
80,123
+69,504
+655% +$1.47M ﹤0.01% 2266
2022
Q1 		$466K Sell
10,619
-39,779
-79% -$1.86M ﹤0.01% 2809
2021
Q4 		$3.07M Buy
50,398
+42,704
+555% +$2.36M 0.01% 1753
2021
Q3 		$320K Hold
7,694
– – ﹤0.01% 2620
2021
Q2 		$234K Sell
7,694
-14,223
-65% -$430K ﹤0.01% 2408
2021
Q1 		$655K Buy
+21,917
New +$565K ﹤0.01% 1834

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's BCYC Position: Q1 2026 in Review

Marshall Wace increased its Bicycle Therapeutics (BCYC) stake by 873% in Q1 2026, buying an estimated $1.93M and bringing the position to 377,335 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Marshall Wace first reported a position in BCYC in Q1 2021 and has held it in 14 quarters since. The position peaked at $7.47M in Q3 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Marshall Wace held 377,335 shares of Bicycle Therapeutics worth $1.75M as of Q1 2026.
  • Marshall Wace bought 338,540 Bicycle Therapeutics shares in Q1 2026, an estimated $1.93M.
  • Bicycle Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1860 holding.
  • Marshall Wace first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • Marshall Wace's Bicycle Therapeutics position peaked at $7.47M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.